Over the previous 2 decades, use of opioids grew dramatically across the United States. In
2015, 37% of American adults were prescribed at least one opioid pain reliever (OPR) 1—3 …

Neonatal abstinence syndrome (NAS) comprises a constellation of drug-withdrawal
symptoms that result from chronic intrauterine exposure to a variety of substances, including …

Neonatal withdrawal symptoms have been noted following prenatal exposure to several
drugs. Examples include opioids, 1, 2 benzodiazepines, 3, 4 mood-stabilizing medications …

Background Neonatal abstinence syndrome (NAS) includes an array of symptoms impacting
opioid-exposed newborns (OEN) owing to postnatal withdrawal from in utero substance …

Neonatal Abstinence Syndrome | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Importance Although opioids are used to treat neonatal abstinence syndrome (NAS), the
best pharmacologic treatment has not been established. Objective To compare the safety …

Over the last decade, rates of opioid pain reliever prescribing grew substantially in the
United States, affecting many segments of the population, including pregnant women (1) …

Background The incidence of neonatal opioid withdrawal is increasing in both Canada and
the United States. However, the degree to which the treatment of pain with opioids, rather …

Importance Neonatal abstinence syndrome, which occurs as a result of in utero opioid
exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial …

Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome in newborns
caused primarily by in utero exposure to opioids. In the United States, the incidence of NAS …